PDCD1 and cancer: miR-138 has been shown to target the PD-1/PD-L1 pathway by downregulating PD-1 expression on T cells or PD-L1 expression on tumor cells in various cancer models, thereby enhancing T cell-mediated immune responses against tumors [52, 53].